MetLife Investment Management’s Akcea Therapeutics Inc AKCA Stock Holding History

MetLife Investment Management’s Portfolio AKCA Stock Details AKCA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-7,945	Closed	-$144K	–	2349
2020 Q3	$144K	Buy	7,945 +589	+8%	+$8.36K	﹤0.01%	2045
2020 Q2	$101K	Hold	7,356	–	–	﹤0.01%	2252
2020 Q1	$105K	Hold	7,356	–	–	﹤0.01%	2046
2019 Q4	$125K	Hold	7,356	–	–	﹤0.01%	2214
2019 Q3	$113K	Hold	7,356	–	–	﹤0.01%	2271
2019 Q2	$172K	Hold	7,356	–	–	﹤0.01%	2117
2019 Q1	$208K	Hold	7,356	–	–	﹤0.01%	1961
2018 Q4	$222K	Hold	7,356	–	–	﹤0.01%	1854
2018 Q3	$258K	Buy	+7,356	New	+$223K	﹤0.01%	1946
2018 Q2	–	Sell	-7,356	Closed	-$188K	–	2247
2018 Q1	$188K	Sell	7,356 -4,106	-36%	-$88.4K	﹤0.01%	1924
2017 Q4	$199K	Buy	+11,462	New	+$225K	﹤0.01%	1928

MetLife Investment Management's AKCA Position: Q4 2020 in Review

MetLife Investment Management sold out of Akcea Therapeutics Inc (AKCA) in Q4 2020, closing a stake of 7,945 shares — an estimated $144K sold.

MetLife Investment Management first reported a position in AKCA in Q4 2017 and held it in 11 quarters. The position peaked at $258K in Q3 2018. 0 funds tracked by Wall St. Rank hold AKCA as of Q4 2020.

MetLife Investment Management reported no remaining Akcea Therapeutics Inc position as of Q4 2020 after selling out during the quarter.
MetLife Investment Management sold 7,945 Akcea Therapeutics Inc shares in Q4 2020, an estimated $144K.
MetLife Investment Management first reported a position in Akcea Therapeutics Inc in Q4 2017 and held it in 11 quarters.
MetLife Investment Management's Akcea Therapeutics Inc position peaked at $258K in Q3 2018.
0 funds tracked by Wall St. Rank held Akcea Therapeutics Inc as of Q4 2020.

Based on MetLife Investment Management's 13F filing for Q4 2020, filed 16 Feb 2021.